INTEGRITES becomes the only Ukrainian law firm to receive recognition of two arbitration experts out of eight representing Ukraine in the international guide Who’s Who Legal: Arbitration 2020. The recently published edition of the guide acknowledges outstanding expertise of Olena Perepelynska, partner and head of International Arbitration at INTEGRITES, and ranks her one of the leading arbitration practitioners. For the third year in a row the guide recognises Serhii Uvarov, counsel, International arbitration and Cross-Border Litigation, among Future Leaders-Non-partners – an honour that is presented annually to young experts, aged 45 or under.
Serving as the President of the Ukrainian Arbitration Association and Member of the ICC International Court of Arbitration, and having over 16 years of experience in international commercial arbitration, Olena Perepelynska is one of the leading experts in the regional arbitration community. She focuses on international arbitration and cross-border dispute resolution, with particular expertise in agribusiness, retail, and natural resources. Since 2003, she has acted as an arbitrator and counsel in more than 120 arbitrations under the arbitration rules of the ICC, LCIA, SCC, SCAI, ICAC at CCIRF, ICAC and MAC at UCCI, IAC at the BelCCI, GAFTA, FOSFA, LMAA, UNCITRAL.
Who is Who Legal: Arbitration 2020 says that Olena Perepelynska is “an eminent arbitration practitioner”, distinguished as “a very dynamic and hard-working lawyer with a strong intellect”.
Serhii Uvarov focuses on the areas of commercial and investment arbitration, arbitration-related litigation and cross-border commercial litigation with particular expertise in energy sector, including renewables. He has been involved in arbitral proceedings under the LCIA, SCC, ICC, UNCITRAL, JAMS, LMAA, ICAC at CCIRF and ICAC at UCCI arbitration rules. He has represented Ukrainian state authorities and state companies before foreign courts and international tribunals. Serhii has also advised clients on transnational insolvency, fraud investigations including anti-bribery probes and enforcement of foreign judicial and arbitral awards in Ukraine. Since 2017, Serhii has served as the Secretary General of the Ukrainian Arbitration Association.
Who is Who Legal: Arbitration 2020 says that he “has great expertise and a very strong professional track-record” in arbitration. One peer commented: “Without a doubt, Serhii is a future star of arbitration in Europe.”
***
Since 1996, Who’s Who Legal has identified the foremost legal practitioners in multiple areas of business law. WWL features over 24,000 of the world’s leading private practice lawyers and 2,500 consulting experts from over 150 national jurisdictions. WWL Arbitration lists 1926 practitioners from 1267 firms in 97 jurisdictions across this practice area.
Original Ukrainian medicines are not available in the markets of the United States and the European Union (EU) over the absence of state support for research in Ukraine, Director General of Research and Industrial Center Borschahivka chemical and pharmaceutical plant (Kyiv) Yulia Zdarevska has said. “Original Ukrainians medicines are not usually introduced in the United States and the EU, not because of their low efficiency, but because of the lack of state support in Ukraine for the development of original drugs at the state or regional levels,” she told Interfax-Ukraine, commenting on the results of research on the market for drugs with insufficient evidence base, initiated by Anti Corruption Action Centre (AntAC) with the support of the International Renaissance Foundation.
Zdarevska said that the lack of registration in the United States or Europe is not proof of the inefficiency of medicines.
“Throughout the world, the registration of the drug in the FDA and EMA is a voluntary decision, not an obligation. Therefore, the substitution of concepts is clearly visible, therefore we believe that the group of drugs mistakenly described in the report as “Medicines Without Proven Effectiveness” should be referred to as” Medicines, the Use of which in the United States or the EU was not Envisaged by the Developer,” she said.
The general director of the plant said that the cost of a full cycle of developing and approving a new original drug in the United States could reach $2 billion.
“These costs today are unaffordable for the Ukrainian pharmaceutical industry,” she said.
Zdarevska said that the studies that pharmaceutical companies conduct to register their own drugs include safety and efficiency studies in accordance with established requirements.
“If these studies are not conducted, the drug cannot be registered. Thus, while demanding the prohibition of drugs not registered in the FDA and EMA, the authors of the research, in the first place, call into question the activities of state (and not only Ukrainian) regulatory authorities,” she said.
At the same time, Zdarevska said that the use of medicines in only one or several countries is a global practice, and the only necessary confirmation of the quality, effectiveness and safety of the drug is the availability of public registration.
She also recalled that in Ukraine for many years there is a pharmacovigilance system that allows the continuous collection, analysis and use of all information on side effects and the experience of clinical use of medicines.
Zdarevska said that Ukrainian pharmaceutical companies also export their medicines to more than 60 countries.
Research and Industrial Center Borschahivka chemical and pharmaceutical plant is among top 20 largest pharmaceutical manufacturers in Ukraine. It is a member of the Association Manufacturers of Medications of Ukraine (AMMU).
